Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Tom Li Stephen"'
Publikováno v:
International Journal of Microbiology, Vol 2010 (2010)
The detection of pathogen-derived molecules as foreign particles by adaptive immune cells triggers T and B lymphocytes to mount protective cellular and humoral responses, respectively. Recent immunological advances elucidated that proteins and some l
Externí odkaz:
https://doaj.org/article/538b28c2e33e4295b075d37b3ddc306b
Autor:
Tom Li Stephen, Mario Fabri, Laura Groneck, Till A Röhn, Helena Hafke, Nirmal Robinson, Jens Rietdorf, David Schrama, Jürgen C Becker, Georg Plum, Martin Krönke, Harald Kropshofer, Wiltrud M Kalka-Moll
Publikováno v:
PLoS Pathogens, Vol 3, Iss 3, p e32 (2007)
Bacterial capsular polysaccharides are virulence factors and are considered T cell-independent antigens. However, the capsular polysaccharide Sp1 from Streptococcus pneumoniae serotype 1 has been shown to activate CD4(+) T cells in a major histocompa
Externí odkaz:
https://doaj.org/article/07159d181ba04d22a42a1ac0dd288456
Autor:
Tom Li Stephen, Qian Zhang, Byung-Kwon Lee, Chao Kong, Rain Sun, Jia Wu, Jie Cui, Hillary Shah, Wenhua Xu, Yun-Yueh Lu, Joshua Whitener, Emily Jackson, Jinping Gan, Francisco Adrian, Liang Schweizer
Publikováno v:
Cancer Research. 83:3477-3477
The CD226 (DNAM-1) axis has emerged as an important immune-modulatory pathway that regulates T cell and NK cell effector functions in the solid tumor microenvironment. Three inhibitory receptors, TIGIT, CD96, and PVRIG, inhibit the activating recepto
Autor:
Eric Haines, Katerine Van Rietschoten, Punit Upadhyaya, Marianna Kleyman, Elizabeth Repash, Tom Li Stephen, Jessica Kublin, Johanna Lahdenranta, Sailaja Battula, Rachel Dods, Kristen Hurov, Jun Ma, Nicholas Keen, Rachid Lani, Gemma Mudd, Philip Brandish, Julia Kristensson, Kevin Mcdonnell, Helen Harrison, Liuhong Chen, Fanglei You
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 1 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 1 (2021)
BackgroundIn contrast to immune checkpoint inhibitors, the use of antibodies as agonists of immune costimulatory receptors as cancer therapeutics has largely failed. We sought to address this problem using a new class of modular synthetic drugs, term